tiprankstipranks
Advertisement
Advertisement

ABBV Stock Latest News

AbbVie’s ABBV-8736 Injection Study Signals Quiet But Meaningful Pipeline Progress
Company AnnouncementsAbbVie’s ABBV-8736 Injection Study Signals Quiet But Meaningful Pipeline Progress
29m ago
ABBV
AbbVie’s Allergan Aesthetics receives approval for Boey in Europe
PremiumThe Fly
AbbVie’s Allergan Aesthetics receives approval for Boey in Europe
3d ago
ABBV
AbbVie’s Bimatoprost SR Extension Data: Why Long-Term Glaucoma Safety Matters for Investors
PremiumCompany Announcements
AbbVie’s Bimatoprost SR Extension Data: Why Long-Term Glaucoma Safety Matters for Investors
5d ago
ABBV
AbbVie price target raised to $260 from $230 at Citi
PremiumThe Fly
AbbVie price target raised to $260 from $230 at Citi
5d ago
ABBV
AbbVie price target raised to $260 from $230 at UBS
PremiumThe Fly
AbbVie price target raised to $260 from $230 at UBS
7d ago
ABBV
AbbVie price target raised to $300 from $258 at BMO Capital
PremiumThe FlyAbbVie price target raised to $300 from $258 at BMO Capital
7d ago
ABBV
The Week That Was, The Week Ahead: Macro and Markets, July 12
Premium
Market News
The Week That Was, The Week Ahead: Macro and Markets, July 12
8d ago
C
GE
2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts
Premium
Market News
2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts
10d ago
ABT
SPX
AbbVie price target raised to $280 from $260 at RBC Capital
PremiumThe Fly
AbbVie price target raised to $280 from $260 at RBC Capital
10d ago
ABBV
AbbVie price target raised to $276 from $234 at BofA
PremiumThe Fly
AbbVie price target raised to $276 from $234 at BofA
10d ago
ABBV
AbbVie price target raised to $295 from $260 at Wells Fargo
PremiumThe Fly
AbbVie price target raised to $295 from $260 at Wells Fargo
10d ago
ABBV
AbbVie price target raised to $280 from $260 at JPMorgan
PremiumThe Fly
AbbVie price target raised to $280 from $260 at JPMorgan
11d ago
ABBV
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
PremiumTipRanks NewswireThe Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
11d ago
LLY
ABBV
AbbVie price target raised to $261 from $249 at Guggenheim
Premium
The Fly
AbbVie price target raised to $261 from $249 at Guggenheim
11d ago
ABBV
AbbVie’s ABBV‑277 Trial Completion: What Early Safety Data Could Mean for Investors
Premium
Company Announcements
AbbVie’s ABBV‑277 Trial Completion: What Early Safety Data Could Mean for Investors
12d ago
ABBV
Closing Bell Movers: Crinetics doubles on Vertex buyout
PremiumThe Fly
Closing Bell Movers: Crinetics doubles on Vertex buyout
14d ago
RTO
STX
AbbVie says Q2 EPS to include unfavorable impact of 17c
PremiumThe Fly
AbbVie says Q2 EPS to include unfavorable impact of 17c
14d ago
ABBV
AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77
PremiumThe Fly
AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77
14d ago
ABBV
AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28
PremiumThe Fly
AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28
14d ago
ABBV
Genmab says EC grants marketing authorization for Tepkinly combo
PremiumThe FlyGenmab says EC grants marketing authorization for Tepkinly combo
14d ago
ABBV
GMAB
AbbVie says Tepkinly combo approved by EC for lymphoma treatment
Premium
The Fly
AbbVie says Tepkinly combo approved by EC for lymphoma treatment
14d ago
ABBV
AbbVie price target raised to $300 from $275 at HSBC
Premium
The Fly
AbbVie price target raised to $300 from $275 at HSBC
14d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >